Breakthrough Pill by Tata Institute Shows Promise in Preventing Cancer Recurrence

The Tata Institute in Mumbai, India's foremost cancer research and treatment institution, claims to have developed a medication that can prevent cancer from returning. The institute's researchers and clinicians toiled for ten years to produce a pill that they believe can prevent cancer from recurring in patients and lessen the negative effects of therapies such as radiation and chemotherapy by 50 percent. Dr. Rajendra Badve, a top cancer surgeon at Tata Memorial Hospital and member of the study group, told NDTV that human cancer cells were implanted in rats, resulting in a tumor. The rats were subsequently subjected to radiation treatment, chemotherapy, and surgery. It was discovered that when cancer cells die, they split into microscopic bits known as chromatin particles. These particles can move to other regions of the body via the circulation, and if they reach healthy cells, they can cause cancer." The Tata Memorial Centre (TMC) discovered that dying cancer cells produce cell-free chromatin particles (cfChPs, or chromosomal fragments), which can transform healthy cells into malignant ones. Some of the cfChPs may merge with healthy chromosomes, resulting in new malignancies. "To find a solution to this problem, doctors gave pro-oxidant tablets with resveratrol and copper (R+Cu) to the rats," the doctor told NDTV. The R+Cu reaction produces oxygen radicals, which degrade chromium particles. When taken orally, 'R+Cu' produces oxygen radicals in the stomach, which are swiftly absorbed and reach the bloodstream. The oxygen radicals kill cfChPs released into the bloodstream, preventing ' metastases' - the transfer of cancer cells from one area of the body to another. The researchers stated that R+Cu inhibits chemotherapy toxicity. The researchers in their presentation called it the "Magic of R+Cu"~ This pill reduces the negative effects of cancer treatment therapy by approximately 50%, and it is also approximately 30% effective in cancer prevention. It is also effective against pancreatic, lung, and oral cancer. "Tata physicians have been working on this tablet for over a decade. The pill is pending certification from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have asked the FSSAI to approve this tablet. After receiving permission, it will be accessible in the market from June to July. This pill will significantly improve cancer treatment," the renowned cancer surgeon stated. "While the budget for the treatment ranges from lakhs to crores, this tablet will be available everywhere for just ₹ 100," said Mr. Singh. The doctor stated that the adverse effects were studied on both rats and people, but the preventative test was only done on rats. The human trials will take around five years to complete. There were difficulties during the research, and many people believed it was a waste of time and resources. But today, everyone is upbeat and thrilled. It's a huge success.